TrialInternational journal of hematology2023

The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.

Yoshitaka Miyakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.